Highlights on Hodgkin lymphoma

Prof. Marc André, hematologist at the CHU UCL Namur curated the most interesting presentations in the field of Hodgkin lymphoma.

He discusses the outcomes of the fil-rouge trial comparing frontline intensified ABVD with PET-adapted ABVD in advanced Hodgkin lymphoma. Prof. André also presents results of the SWOG S1826 with nivolumab in advanced stage classic Hodgkin lymphoma (CHL).

Prof. André also briefly touches upon the use of anti-PD- treatment in elderly patients and describes a posthoc analysis estimating the relative efficacy of the LAG-3 inhibitor favezelimab in anti-PD-1-refractory CHL.

And finally, Prof. André discusses the utility of circulating tumor DNA to identify distinct Hodgkin lymphoma subtypes.

With the educational support of: